In the REIMAGINE 1 trial, the most commonly reported adverse events (AEs) were gastrointestinal (GI)-related, occurring in 33/62 (53%) participants in the CagriSema 2.4 mg/2.4 mg group, 28/63 (44%) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results